Friday 19 October 2012

Actavis forecasts 2012 sales in excess of 2 billion euros

FRANKFURT (Reuters) - Actavis, the Swiss generic drugmaker that Watson Pharmaceuticals is taking over, said revenue would rise to more than 2 billion euros ($2.6 billion) this year, driven by patent expiries in Europe and strong demand in the United States. Sales would increase by a double-digit percentage rate in 2012, Actavis Chief Executive Claudio Albrecht told Reuters late on Thursday, also citing growth in Far Eastern markets such as Indonesia. "In terms of profits we are growing even faster than sales," he added. Actavis posted 2011 sales of $2. ... via Health News Headlines - Yahoo! News Read More Here..

No comments:

Post a Comment